Financhill
Sell
23

SNDX Quote, Financials, Valuation and Earnings

Last price:
$13.04
Seasonality move :
-1.51%
Day range:
$12.89 - $13.32
52-week range:
$12.06 - $25.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.87x
Volume:
767.1K
Avg. volume:
2.3M
1-year change:
-42.83%
Market cap:
$1.1B
Revenue:
$23.7M
EPS (TTM):
-$3.73

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SNDX
Syndax Pharmaceuticals
$86.5M -$0.23 -- -46.18% $36.14
MCRB
Seres Therapeutics
-- -$0.20 -100% -32.98% $3.82
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SNDX
Syndax Pharmaceuticals
$12.95 $36.14 $1.1B -- $0.00 0% --
MCRB
Seres Therapeutics
$0.69 $3.82 $117.8M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.1M -- $0.00 0% 0.07x
OGEN
Oragenics
$0.28 $1.00 $3.4M -- $0.00 0% 1.10x
PTN
Palatin Technologies
$0.79 $7.00 $20.6M -- $0.00 0% --
TOVX
Theriva Biologics
$1.15 $6.00 $3.2M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SNDX
Syndax Pharmaceuticals
54.4% 0.475 30.34% 5.76x
MCRB
Seres Therapeutics
-- -1.064 -- --
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
OGEN
Oragenics
-- 3.509 -- --
PTN
Palatin Technologies
-- -1.737 -- 0.99x
TOVX
Theriva Biologics
-- -2.868 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SNDX
Syndax Pharmaceuticals
-- -$96.4M -64.3% -74.65% -1163.58% -$57.4M
MCRB
Seres Therapeutics
-- -$29.2M -- -- -- -$34.8M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Syndax Pharmaceuticals vs. Competitors

  • Which has Higher Returns SNDX or MCRB?

    Seres Therapeutics has a net margin of -1226.16% compared to Syndax Pharmaceuticals's net margin of --. Syndax Pharmaceuticals's return on equity of -74.65% beat Seres Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNDX
    Syndax Pharmaceuticals
    -- -$1.10 $631.8M
    MCRB
    Seres Therapeutics
    -- $0.58 --
  • What do Analysts Say About SNDX or MCRB?

    Syndax Pharmaceuticals has a consensus price target of $36.14, signalling upside risk potential of 179.1%. On the other hand Seres Therapeutics has an analysts' consensus of $3.82 which suggests that it could grow by 454.36%. Given that Seres Therapeutics has higher upside potential than Syndax Pharmaceuticals, analysts believe Seres Therapeutics is more attractive than Syndax Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNDX
    Syndax Pharmaceuticals
    10 1 0
    MCRB
    Seres Therapeutics
    4 1 0
  • Is SNDX or MCRB More Risky?

    Syndax Pharmaceuticals has a beta of 0.925, which suggesting that the stock is 7.546% less volatile than S&P 500. In comparison Seres Therapeutics has a beta of 2.186, suggesting its more volatile than the S&P 500 by 118.578%.

  • Which is a Better Dividend Stock SNDX or MCRB?

    Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seres Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Seres Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SNDX or MCRB?

    Syndax Pharmaceuticals quarterly revenues are $7.7M, which are larger than Seres Therapeutics quarterly revenues of --. Syndax Pharmaceuticals's net income of -$94.2M is lower than Seres Therapeutics's net income of $88.8M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Seres Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus -- for Seres Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNDX
    Syndax Pharmaceuticals
    -- -- $7.7M -$94.2M
    MCRB
    Seres Therapeutics
    -- -- -- $88.8M
  • Which has Higher Returns SNDX or NBY?

    NovaBay Pharmaceuticals has a net margin of -1226.16% compared to Syndax Pharmaceuticals's net margin of -49.65%. Syndax Pharmaceuticals's return on equity of -74.65% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNDX
    Syndax Pharmaceuticals
    -- -$1.10 $631.8M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About SNDX or NBY?

    Syndax Pharmaceuticals has a consensus price target of $36.14, signalling upside risk potential of 179.1%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that Syndax Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Syndax Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNDX
    Syndax Pharmaceuticals
    10 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is SNDX or NBY More Risky?

    Syndax Pharmaceuticals has a beta of 0.925, which suggesting that the stock is 7.546% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock SNDX or NBY?

    Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SNDX or NBY?

    Syndax Pharmaceuticals quarterly revenues are $7.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Syndax Pharmaceuticals's net income of -$94.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNDX
    Syndax Pharmaceuticals
    -- -- $7.7M -$94.2M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns SNDX or OGEN?

    Oragenics has a net margin of -1226.16% compared to Syndax Pharmaceuticals's net margin of --. Syndax Pharmaceuticals's return on equity of -74.65% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNDX
    Syndax Pharmaceuticals
    -- -$1.10 $631.8M
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About SNDX or OGEN?

    Syndax Pharmaceuticals has a consensus price target of $36.14, signalling upside risk potential of 179.1%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 257.14%. Given that Oragenics has higher upside potential than Syndax Pharmaceuticals, analysts believe Oragenics is more attractive than Syndax Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNDX
    Syndax Pharmaceuticals
    10 1 0
    OGEN
    Oragenics
    0 1 0
  • Is SNDX or OGEN More Risky?

    Syndax Pharmaceuticals has a beta of 0.925, which suggesting that the stock is 7.546% less volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

  • Which is a Better Dividend Stock SNDX or OGEN?

    Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SNDX or OGEN?

    Syndax Pharmaceuticals quarterly revenues are $7.7M, which are larger than Oragenics quarterly revenues of --. Syndax Pharmaceuticals's net income of -$94.2M is lower than Oragenics's net income of -$2.5M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus 1.10x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNDX
    Syndax Pharmaceuticals
    -- -- $7.7M -$94.2M
    OGEN
    Oragenics
    1.10x -- -- -$2.5M
  • Which has Higher Returns SNDX or PTN?

    Palatin Technologies has a net margin of -1226.16% compared to Syndax Pharmaceuticals's net margin of -2357.27%. Syndax Pharmaceuticals's return on equity of -74.65% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNDX
    Syndax Pharmaceuticals
    -- -$1.10 $631.8M
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About SNDX or PTN?

    Syndax Pharmaceuticals has a consensus price target of $36.14, signalling upside risk potential of 179.1%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that Palatin Technologies has higher upside potential than Syndax Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Syndax Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNDX
    Syndax Pharmaceuticals
    10 1 0
    PTN
    Palatin Technologies
    0 0 0
  • Is SNDX or PTN More Risky?

    Syndax Pharmaceuticals has a beta of 0.925, which suggesting that the stock is 7.546% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock SNDX or PTN?

    Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SNDX or PTN?

    Syndax Pharmaceuticals quarterly revenues are $7.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Syndax Pharmaceuticals's net income of -$94.2M is lower than Palatin Technologies's net income of -$2.4M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNDX
    Syndax Pharmaceuticals
    -- -- $7.7M -$94.2M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M
  • Which has Higher Returns SNDX or TOVX?

    Theriva Biologics has a net margin of -1226.16% compared to Syndax Pharmaceuticals's net margin of --. Syndax Pharmaceuticals's return on equity of -74.65% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNDX
    Syndax Pharmaceuticals
    -- -$1.10 $631.8M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About SNDX or TOVX?

    Syndax Pharmaceuticals has a consensus price target of $36.14, signalling upside risk potential of 179.1%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 419.93%. Given that Theriva Biologics has higher upside potential than Syndax Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Syndax Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNDX
    Syndax Pharmaceuticals
    10 1 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is SNDX or TOVX More Risky?

    Syndax Pharmaceuticals has a beta of 0.925, which suggesting that the stock is 7.546% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

  • Which is a Better Dividend Stock SNDX or TOVX?

    Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SNDX or TOVX?

    Syndax Pharmaceuticals quarterly revenues are $7.7M, which are larger than Theriva Biologics quarterly revenues of --. Syndax Pharmaceuticals's net income of -$94.2M is lower than Theriva Biologics's net income of -$4.4M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNDX
    Syndax Pharmaceuticals
    -- -- $7.7M -$94.2M
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock